Skip to main content
Erschienen in: Wiener klinische Wochenschrift 15-16/2016

01.08.2016 | original article

Predictors of 1-year visual outcome in OCT analysis comparing ranibizumab monotherapy versus combination therapy with PDT in exsudative age-related macular degeneration

verfasst von: Birgit Weingessel, MD, Kata Mihaltz, MD, PhD, Pia Veronika Vécsei-Marlovits, MD

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 15-16/2016

Einloggen, um Zugang zu erhalten

Summary

Aim

The aim of this study was to find predictive factors of 1-year visual outcome, analyzing novel optical coherence tomography (OCT) biomarkers in exsudative age-related macular degeneration (choroidal neovascularization (CNV)) in two groups of different treatment modalities.

Methods

In all, 34 consecutive patients with new-onset CNV were randomized 1:1 to receive either ranibizumab monotherapy or ranibizumab combined with photodynamic therapy (PDT) with verteporfin. After three initial injections with ranibizumab, re-treatment was performed according to an as-needed scheme; PDT was performed once at baseline. Best-corrected visual acuity (BCVA) and OCT parameters like central macular volume (CMV), central macular thickness (or central retinal thickness (CRT)), subretinal and intraretinal fluid, fibrovascular lesion thickness, or inner segment/outer segment (IS/OS) junction were analyzed.

Results

After 12 months, a visual gain of 6.1 letters was found in the monotherapy group, whereas patients in the combination therapy group lost − 4.8 letters from baseline to the 12-month visit. CMV and CRT decreased considerably between baseline and month 2–3 in both groups, with a following slight increase until month 12. Additional application of PDT had negative effect to 12-month BCVA, whereas higher baseline BCVA and integrity of the IS/OS junction at month 12 had positive effect to 12-month BCVA.

Conclusions

Better baseline BCVA and the integrity of IS/OS junction at 12-month visit were the most important predictive factors for final BCVA. Combination therapy caused worse final BCVA and a higher degree of IS/OS disruption.
Literatur
1.
Zurück zum Zitat Bressler NM, Bressler SB, Congdon NG, et al. Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch Ophthalmol. 2003;121:1621–4.CrossRefPubMed Bressler NM, Bressler SB, Congdon NG, et al. Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch Ophthalmol. 2003;121:1621–4.CrossRefPubMed
2.
Zurück zum Zitat Friedman DS, O’Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122:564–72.CrossRefPubMed Friedman DS, O’Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122:564–72.CrossRefPubMed
3.
Zurück zum Zitat Klein R, Peto T, Bird A, et al. The epidemiology of age-related macular degeneration. Am J Ophthalmol. 2004;137:486–95.CrossRefPubMed Klein R, Peto T, Bird A, et al. The epidemiology of age-related macular degeneration. Am J Ophthalmol. 2004;137:486–95.CrossRefPubMed
4.
Zurück zum Zitat Bressler NM, Bressler SB, Seddon JM, et al. Drusen characteristics in patients with exudative versus non-exudative age-related macular degeneration. Retina. 1988;8:109–14.CrossRefPubMed Bressler NM, Bressler SB, Seddon JM, et al. Drusen characteristics in patients with exudative versus non-exudative age-related macular degeneration. Retina. 1988;8:109–14.CrossRefPubMed
5.
Zurück zum Zitat Macular Photocoagulation Study Group. Five-year follow-up of fellow eyes of patients with age-related macular degeneration and unilateral extrafoveal choroidal neovascularization. Arch Ophthalmol. 1993;111:1189–99.CrossRef Macular Photocoagulation Study Group. Five-year follow-up of fellow eyes of patients with age-related macular degeneration and unilateral extrafoveal choroidal neovascularization. Arch Ophthalmol. 1993;111:1189–99.CrossRef
6.
Zurück zum Zitat Barouch FC, Miller JW. Anti-vascular endothelial growth factor strategies for the treatment of choroidal neovascularization from age-related macular degeneration. Int Ophthalmol Clin. 2004;44:23–32.CrossRefPubMed Barouch FC, Miller JW. Anti-vascular endothelial growth factor strategies for the treatment of choroidal neovascularization from age-related macular degeneration. Int Ophthalmol Clin. 2004;44:23–32.CrossRefPubMed
7.
Zurück zum Zitat Carneiro AM, Falcao MS, Brandao EM, et al. Intravitreal bevacizumab for neovascular age-related macular degeneration with or without prior treatment with photodynamic therapy: one-year results. Retina. 2010;30:85–92.CrossRefPubMed Carneiro AM, Falcao MS, Brandao EM, et al. Intravitreal bevacizumab for neovascular age-related macular degeneration with or without prior treatment with photodynamic therapy: one-year results. Retina. 2010;30:85–92.CrossRefPubMed
8.
Zurück zum Zitat Kaiser PK, Boyer DS, Garcia R, et al. Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Ophthalmology. 2009;116:747–55.CrossRefPubMed Kaiser PK, Boyer DS, Garcia R, et al. Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Ophthalmology. 2009;116:747–55.CrossRefPubMed
9.
Zurück zum Zitat Bressler NM. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol. 2001;119:198–207.PubMed Bressler NM. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol. 2001;119:198–207.PubMed
10.
Zurück zum Zitat Kaiser PK. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP report no. 8. Graefes Arch Clin Exp Ophthalmol. 2006;244:1132–42.CrossRefPubMed Kaiser PK. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP report no. 8. Graefes Arch Clin Exp Ophthalmol. 2006;244:1132–42.CrossRefPubMed
11.
Zurück zum Zitat Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432–44.CrossRefPubMed Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432–44.CrossRefPubMed
12.
Zurück zum Zitat Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–31.CrossRefPubMed Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–31.CrossRefPubMed
13.
Zurück zum Zitat Spielberg L, Leys A. Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years. Graefes Arch Clin Exp Ophthalmol. 2010;248:943–56.CrossRefPubMed Spielberg L, Leys A. Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years. Graefes Arch Clin Exp Ophthalmol. 2010;248:943–56.CrossRefPubMed
14.
Zurück zum Zitat Ladewig MS, Karl SE, Hamelmann V, et al. Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2008;246:17–25.CrossRef Ladewig MS, Karl SE, Hamelmann V, et al. Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2008;246:17–25.CrossRef
15.
Zurück zum Zitat Lim JY, Lee SY, Kim JG, et al. Intravitreal bevacizumab alone versus in combination with photodynamic therapy for the treatment of neovascular maculopathy in patients aged 50 years or older: 1-year results of a prospective clinical study. Acta Ophthalmol. 2012;90:61–7.CrossRefPubMed Lim JY, Lee SY, Kim JG, et al. Intravitreal bevacizumab alone versus in combination with photodynamic therapy for the treatment of neovascular maculopathy in patients aged 50 years or older: 1-year results of a prospective clinical study. Acta Ophthalmol. 2012;90:61–7.CrossRefPubMed
16.
Zurück zum Zitat Mataix J, Palacios E, Carmen DM, et al. Combined ranibizumab and photodynamic therapy to treat exudative age-related macular degeneration: an option for improving treatment efficiency. Retina. 2010;30:1190–6.CrossRefPubMed Mataix J, Palacios E, Carmen DM, et al. Combined ranibizumab and photodynamic therapy to treat exudative age-related macular degeneration: an option for improving treatment efficiency. Retina. 2010;30:1190–6.CrossRefPubMed
17.
Zurück zum Zitat Ozturk T, Oner H, Saatci AO, et al. Low-fluence photodynamic therapy combinations in the treatment of exudative age-related macular degeneration. Int J Ophthalmol. 2012;5:377–83.PubMedPubMedCentral Ozturk T, Oner H, Saatci AO, et al. Low-fluence photodynamic therapy combinations in the treatment of exudative age-related macular degeneration. Int J Ophthalmol. 2012;5:377–83.PubMedPubMedCentral
18.
Zurück zum Zitat Vallance JH, Johnson B, Majid MA, et al. A randomised prospective double-masked exploratory study comparing combination photodynamic treatment and intravitreal ranibizumab vs intravitreal ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration. Eye (Lond). 2010;24:1561–7.CrossRef Vallance JH, Johnson B, Majid MA, et al. A randomised prospective double-masked exploratory study comparing combination photodynamic treatment and intravitreal ranibizumab vs intravitreal ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration. Eye (Lond). 2010;24:1561–7.CrossRef
19.
Zurück zum Zitat Kaiser PK, Boyer DS, Cruess AF, et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study. Ophthalmology. 2012;119:1001–10.CrossRefPubMed Kaiser PK, Boyer DS, Cruess AF, et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study. Ophthalmology. 2012;119:1001–10.CrossRefPubMed
20.
Zurück zum Zitat Larsen M, Schmidt-Erfurth U, Lanzetta P, et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results. Ophthalmology. 2012;119:992–1000.CrossRefPubMed Larsen M, Schmidt-Erfurth U, Lanzetta P, et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results. Ophthalmology. 2012;119:992–1000.CrossRefPubMed
21.
Zurück zum Zitat Potter MJ, Claudio CC, Szabo SM. A randomised trial of bevacizumab and reduced light dose photodynamic therapy in age-related macular degeneration: the VIA study. Br J Ophthalmol. 2010;94:174–9.CrossRefPubMed Potter MJ, Claudio CC, Szabo SM. A randomised trial of bevacizumab and reduced light dose photodynamic therapy in age-related macular degeneration: the VIA study. Br J Ophthalmol. 2010;94:174–9.CrossRefPubMed
22.
Zurück zum Zitat Wolf-Schnurrbusch UE, Brinkmann CK, Berger L, et al. Effects of combination therapy with verteporfin photodynamic therapy and ranibizumab in patients with age-related macular degeneration. Acta Ophthalmol. 2011;89:585–90.CrossRefPubMed Wolf-Schnurrbusch UE, Brinkmann CK, Berger L, et al. Effects of combination therapy with verteporfin photodynamic therapy and ranibizumab in patients with age-related macular degeneration. Acta Ophthalmol. 2011;89:585–90.CrossRefPubMed
23.
Zurück zum Zitat Bloch SB, la Cour M, Sander B, et al. Predictors of 1-year visual outcome in neovascular age-related macular degeneration following intravitreal ranibizumab treatment. Acta Ophthalmol. 2013;91:42–7.CrossRef Bloch SB, la Cour M, Sander B, et al. Predictors of 1-year visual outcome in neovascular age-related macular degeneration following intravitreal ranibizumab treatment. Acta Ophthalmol. 2013;91:42–7.CrossRef
24.
Zurück zum Zitat Gamulescu MA, Panagakis G, Theek C, et al. Predictive Factors in OCT analysis for visual outcome in exudative AMD. J Ophthalmol. 2012;2012:851648.CrossRefPubMedPubMedCentral Gamulescu MA, Panagakis G, Theek C, et al. Predictive Factors in OCT analysis for visual outcome in exudative AMD. J Ophthalmol. 2012;2012:851648.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Hayashi H, Yamashiro K, Tsujikawa A, et al. Association between foveal photoreceptor integrity and visual outcome in neovascular age-related macular degeneration. Am J Ophthalmol. 2009;148:83–9.CrossRefPubMed Hayashi H, Yamashiro K, Tsujikawa A, et al. Association between foveal photoreceptor integrity and visual outcome in neovascular age-related macular degeneration. Am J Ophthalmol. 2009;148:83–9.CrossRefPubMed
26.
Zurück zum Zitat Keane PA, Heussen FM, Ouyang Y, et al. Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2012;53:1152–61.CrossRefPubMedPubMedCentral Keane PA, Heussen FM, Ouyang Y, et al. Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2012;53:1152–61.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Keane PA, Patel PJ, Liakopoulos S, et al. Evaluation of age-related macular degeneration with optical coherence tomography. Surv Ophthalmol. 2012;57:389–414.CrossRefPubMed Keane PA, Patel PJ, Liakopoulos S, et al. Evaluation of age-related macular degeneration with optical coherence tomography. Surv Ophthalmol. 2012;57:389–414.CrossRefPubMed
28.
Zurück zum Zitat Lie S, Aue A, Sacu S, et al. Time-course and characteristic morphology of retinal changes following combination of verteporfin therapy and intravitreal triamcinolone in neovascular age-related macular degeneration. Acta Ophthalmol. 2010;88:212–7.CrossRefPubMed Lie S, Aue A, Sacu S, et al. Time-course and characteristic morphology of retinal changes following combination of verteporfin therapy and intravitreal triamcinolone in neovascular age-related macular degeneration. Acta Ophthalmol. 2010;88:212–7.CrossRefPubMed
29.
Zurück zum Zitat Okada K, Kubota-Taniai M, Kitahashi M, et al. Changes in visual function and thickness of macula after photodynamic therapy for age-related macular degeneration. Clin Ophthalmol. 2009;3:483–8.CrossRefPubMedPubMedCentral Okada K, Kubota-Taniai M, Kitahashi M, et al. Changes in visual function and thickness of macula after photodynamic therapy for age-related macular degeneration. Clin Ophthalmol. 2009;3:483–8.CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Sayed KM, Naito T, Nagasawa T, et al. Early visual impacts of optical coherence tomographic parameters in patients with age-related macular degeneration following the first versus repeated ranibizumab injection. Graefes Arch Clin Exp Ophthalmol. 2011;249:1449–58.CrossRefPubMed Sayed KM, Naito T, Nagasawa T, et al. Early visual impacts of optical coherence tomographic parameters in patients with age-related macular degeneration following the first versus repeated ranibizumab injection. Graefes Arch Clin Exp Ophthalmol. 2011;249:1449–58.CrossRefPubMed
31.
Zurück zum Zitat Boyer DS, Antoszyk AN, Awh CC, et al. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007;114:246–52.CrossRefPubMed Boyer DS, Antoszyk AN, Awh CC, et al. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007;114:246–52.CrossRefPubMed
32.
Zurück zum Zitat Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008;145:239–48.CrossRefPubMed Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008;145:239–48.CrossRefPubMed
33.
Zurück zum Zitat Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143:566–83.CrossRefPubMed Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143:566–83.CrossRefPubMed
34.
Zurück zum Zitat Kaiser PK, Brown DM, Zhang K, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol. 2007;144:850–7.CrossRefPubMed Kaiser PK, Brown DM, Zhang K, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol. 2007;144:850–7.CrossRefPubMed
35.
Zurück zum Zitat Schadlu R, Kymes SM, Apte RS. Combined photodynamic therapy and intravitreal triamcinolone for neovascular age-related macular degeneration: effect of initial visual acuity on treatment response. Graefes Arch Clin Exp Ophthalmol. 2007;245:1667–72.CrossRefPubMed Schadlu R, Kymes SM, Apte RS. Combined photodynamic therapy and intravitreal triamcinolone for neovascular age-related macular degeneration: effect of initial visual acuity on treatment response. Graefes Arch Clin Exp Ophthalmol. 2007;245:1667–72.CrossRefPubMed
36.
Zurück zum Zitat Rudnisky CJ, Liu C, Ng M, et al. Intravitreal bevacizumab alone versus combined verteporfin photodynamic therapy and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration: visual acuity after 1 year of follow-up. Retina. 2010;30:548–54.CrossRefPubMed Rudnisky CJ, Liu C, Ng M, et al. Intravitreal bevacizumab alone versus combined verteporfin photodynamic therapy and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration: visual acuity after 1 year of follow-up. Retina. 2010;30:548–54.CrossRefPubMed
37.
Zurück zum Zitat Krebs I, Vecsei Marlovits V, Bodenstorfer J, et al. Comparison of Ranibizumab monotherapy versus combination of Ranibizumab with photodynamic therapy with neovascular age-related macular degeneration. Acta Ophthalmol. 2013;91:178–83.CrossRef Krebs I, Vecsei Marlovits V, Bodenstorfer J, et al. Comparison of Ranibizumab monotherapy versus combination of Ranibizumab with photodynamic therapy with neovascular age-related macular degeneration. Acta Ophthalmol. 2013;91:178–83.CrossRef
Metadaten
Titel
Predictors of 1-year visual outcome in OCT analysis comparing ranibizumab monotherapy versus combination therapy with PDT in exsudative age-related macular degeneration
verfasst von
Birgit Weingessel, MD
Kata Mihaltz, MD, PhD
Pia Veronika Vécsei-Marlovits, MD
Publikationsdatum
01.08.2016
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 15-16/2016
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-015-0772-0

Weitere Artikel der Ausgabe 15-16/2016

Wiener klinische Wochenschrift 15-16/2016 Zur Ausgabe